Novartis plans to seek quick regulatory approvals from health authorities for the drug, known as GanLum, which would be the ...

Dr. Ghyslain Mombo-Ngoma led a study in Gabon in which researchers gave a single-dose treatment combining an artemisinin with ...

The drug, known as GanLum, is made by Swiss pharmaceutical giant Novartis. In a late-stage trial, it worked about as well as ...

The best drug to fight malaria is facing increased resistance from the parasites it fights. Now there's an alternative in the ...

Hundreds of malaria patients participating in a Phase 3 clinical trial in Gabon in West Africa were cured via a single dose ...

Promising results from a new malaria drug offer hope against emerging drug resistance in Africa. In a clinical trial, ...

Novartis said its experimental treatment cured more than 99% of malaria cases in the trial, marking a big step toward ...

A new anti-malaria drug with a cure rate of over 97 per cent has been developed by scientists. The drug is the first to be ...

In what experts are calling a breakthrough in the global fight against malaria, a new next-generation drug candidate — GanLum (ganaplacide/lumefantrine, KLU156) — has shown a 97% cure rate in Phase 3 ...

Scientists have created the first new anti- malaria drug in a quarter of a century to combat resistance to existing ...